Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator

Neuroscience

Volumn 304, Issue , 2015, Pages 90-100

  Cui, X ^a   Pertile, R ^a   Liu, P ^a   Eyles, D W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Centre for Mental Health Research   (Australia)

Author keywords

1,25(OH)2< inf>D3< inf>; Developmental vitamin D (DVD) deficiency; Dopamine; N cadherin; Proliferation; Tyrosine hydroxylase

Indexed keywords

CALCITRIOL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE CELL ADHESION MOLECULE; TYROSINE 3 MONOOXYGENASE; VITAMIN D RECEPTOR; CADHERIN; CALCITRIOL RECEPTOR; CDH2 PROTEIN, HUMAN; DOPAMINE; LEUKOCYTE ANTIGEN; MESSENGER RNA; N-CADHERIN, RAT; NERVE PROTEIN; STEROID; VITAMIN D;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; VITAMIN D DEFICIENCY; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE TISSUE PROTEINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEROIDS; TRANSFECTION; TYROSINE 3-MONOOXYGENASE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84938338728     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.07.048     Document Type: Article

References (66)

1. Agholme L., Lindstrom T., Kagedal K., Marcusson J., Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 2010, 20:1069-1082.
2. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001, 21:98-108.
3. Brown J., Bianco J.I., McGrath J.J., Eyles D.W. 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003, 343:139-143.
4. Cass W.A., Manning M.W. GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine. J Neurosci 1999, 19:1416-1423.
5. Cass W.A., Peters L.E., Fletcher A.M., Yurek D.M. Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats. Neurochem Int 2012, 60:186-191.
6. Cass W.A., Peters L.E., Fletcher A.M., Yurek D.M. Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats. Neurochem Res 2014, 39:1467-1476.
7. Cass W.A., Smith M.P., Peters L.E. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 2006, 1074:261-271.
8. Celli A., Treves C., Nassi P., Stio M. Role of 1,25-dihydroxyvitamin D-3 and extracellular calcium in the regulation of proliferation in cultured SH-SY5Y human neuroblastoma cells. Neurochem Res 1999, 24:691-698.
9. Chattopadhyay N., MacLeod R.J., Tfelt-Hansen J., Brown E.M. 1alpha,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab 2003, 284:E219-E227.
10. Cui X., McGrath J.J., Burne T.H., Mackay-Sim A., Eyles D.W. Maternal vitamin D depletion alters neurogenesis in the developing rat brain. Int J Dev Neurosci 2007, 25:227-232.
11. Cui X., Pelekanos M., Burne T.H., McGrath J.J., Eyles D.W. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. Neurosci Lett 2010, 486:220-223.
12. Cui X., Pelekanos M., Liu P.Y., Burne T.H., McGrath J.J., Eyles D.W. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience 2013, 236:77-87.
13. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008, 65:1348-1352.
14. Evatt M.L., DeLong M.R., Kumari M., Auinger P., McDermott M.P., Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011, 68:314-319.
15. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D3 and brain development. Neuroscience 2003, 118:641-653.
16. Eyles D, Burne THJ, Alexander S, Cui XY, McGrath JJ (2011) The developmental vitamin D (DVD) model of schizophrenia. In: Animal models of schizophrenia and related disorders, Vol. 59 (O'Donnell P, ed), pp 113-125. New York: Human Press.
17. Eyles D., Cui X.Y., Pelekanos M., Kesby J., Burne T., McGrath J. Developmental vitamin D deficiency (DVD) and brain dopamine ontogeny. Schizophr Res 2010, 117:169.
18. Eyles D., Feldon J., Meyer U. Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry 2012, 2:e81.
19. Eyles D.W., Burne T.H., McGrath J.J. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2013, 34:47-64.
20. Eyles D.W., Feron F., Cui X., Kesby J.P., Harms L.H., Ko P., McGrath J.J., Burne T.H. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009, 34(Suppl. 1):S247-S257.
21. Eyles D.W., Liu P.Y., Josh P., Cui X. Intracellular distribution of the vitamin D receptor in the brain: comparison with classic target tissues and redistribution with development. Neuroscience 2014, 268:1-9.
22. Gates M.A., Torres E.M., White A., Fricker-Gates R.A., Dunnett S.B. Re-examining the ontogeny of substantia nigra dopamine neurons. Eur J Neurosci 2006, 23:1384-1390.
23. Gumireddy K., Ikegaki N., Phillips P.C., Sutton L.N., Reddy C.D. Effect of 20-epi-1alpha,25-dihydroxyvitamin D3 on the proliferation of human neuroblastoma: role of cell cycle regulators and the Myc-Id2 pathway. Biochem Pharmacol 2003, 65:1943-1955.
24. Gumireddy K., Reddy G.S., Ikegaki N., Binderup L., Sutton L.N., Phillips P.C., Reddy C.D. Anti-proliferative effects of 20-epi-vitamin-D3 analogue, KH1060 in human neuroblastoma: induction of RAR-beta and p21(Cip1). Cancer Lett 2003, 190:51-60.
25. Halbleib J.M., Nelson W.J. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006, 20:3199-3214.
26. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13:325-349.
27. Hawes J.E., Tesic D., Whitehouse A.J., Zosky G.R., Smith J.T., Wyrwoll C.S. Maternal vitamin D deficiency alters fetal brain development in the BALB/c mouse. Behav Brain Res 2015, 286:192-200.
28. Jeong H., Kim M.S., Kim S.W., Kim K.S., Seol W. Regulation of tyrosine hydroxylase gene expression by retinoic acid receptor. J Neurochem 2006, 98:386-394.
29. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998, 78:1193-1231.
30. Kelly M.A., Marion S.L., Donaldson C.A., Pike J.W., Haussler M.R. A variant form of the 1,25-dihydroxyvitamin D3 receptor with low apparent hormone affinity in cultured monkey kidney cells (LLC-MK2). A model for tissue resistance to vitamin D. J Biol Chem 1985, 260:1545-1549.
31. Kesby J.P., Burne T.H., McGrath J.J., Eyles D.W. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: an animal model of schizophrenia. Biol Psychiatry 2006, 60:591-596.
32. Kesby J.P., Cui X., O'Loan J., McGrath J.J., Burne T.H., Eyles D.W. Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology 2010, 208:159-168.
33. Kesby J.P., Cui X.Y., Ko P., McGrath J.J., Burne T.H.J., Eyles D.W. Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neurosci Lett 2009, 461:155-158.
34. Kim J.S., Ryu S.Y., Yun I., Kim W.J., Lee K.S., Park J.W., Kim Y.I. 1alpha,25-dihydroxyvitamin D(3) protects dopaminergic neurons in rodent models of Parkinson's disease through inhibition of microglial activation. J Clin Neurol 2006, 2:252-257.
35. Knekt P., Kilkkinen A., Rissanen H., Marniemi J., Saaksjarvi K., Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010, 67:808-811.
36. Ko P., Burkert R., McGrath J., Eyles D. Maternal vitamin D3 deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res Dev Brain Res 2004, 153:61-68.
37. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011, 51:311-336.
38. Lopes N., Carvalho J., Duraes C., Sousa B., Gomes M., Costa J.L., Oliveira C., Paredes J., Schmitt F. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res 2012, 32:249-257.
39. Maharjan S., Serova L., Sabban E.L. Transcriptional regulation of tyrosine hydroxylase by estrogen: opposite effects with estrogen receptors alpha and beta and interactions with cyclic AMP. J Neurochem 2005, 93:1502-1514.
40. Marinescu V.D., Kohane I.S., Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinf 2005, 6:79.
41. McGrath J., Feron F., Eyles D., Mackay-Sim A. Vitamin D: the neglected neurosteroid?. Trends Neurosci 2001, 24:570-572.
42. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., Norgaard-Pedersen B., Hougaard D.M., Mortensen P.B. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010, 67:889-894.
43. Naveilhan P., Neveu I., Wion D., Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. NeuroReport 1996, 7:2171-2175.
44. Newmark H.L., Newmark J. Vitamin D and Parkinson's disease-a hypothesis. Mov Disord 2007, 22:461-468.
45. Ordonez-Moran P., Larriba M.J., Palmer H.G., Valero R.A., Barbachano A., Dunach M., de Herreros A.G., Villalobos C., Berciano M.T., Lafarga M., Munoz A. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J Cell Biol 2008, 183:697-710.
46. Orme R.P., Bhangal M.S., Fricker R.A. Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. PLoS One 2013, 8:e62040.
47. Palmer H.G., Gonzalez-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., Quintanilla M., Cano A., de Herreros A.G., Lafarga M., Munoz A. Vitamin D-3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001, 154:369-387.
48. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., Berciano M.T., Lafarga M., Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
49. Peterson A.L., Mancini M., Horak F.B. The relationship between balance control and vitamin D in Parkinson's disease - a pilot study. Mov Disord 2013, 28:1133-1137.
50. Puchacz E., Stumpf W.E., Stachowiak E.K., Stachowiak M.K. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res 1996, 36:193-196.
51. Reynolds B.A., Rietze R.L. Neural stem cells and neurospheres - re-evaluating the relationship. Nat Methods 2005, 2:333-336.
52. Ryhanen S., Jaaskelainen T., Saarela J.T., Maenpaa P.H. Inhibition of proliferation and induction of differentiation of osteoblastic cells by a novel 1,25-dihydroxyvitamin D3 analog with an extensively modified side chain (CB1093). J Cell Biochem 1998, 70:414-424.
53. Sakane F., Miyamoto Y. N-cadherin regulates the proliferation and differentiation of ventral midbrain dopaminergic progenitors. Dev Neurobiol 2013, 73:518-529.
54. Sanchez B., Lopez-Martin E., Segura C., Labandeira-Garcia J.L., Perez-Fernandez R. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res Mol Brain Res 2002, 108:143-146.
55. Sanchez B., Relova J.L., Gallego R., Ben-Batalla I., Perez-Fernandez R. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res 2009, 87:723-732.
56. Shimamura K., Takeichi M. Local and transient expression of E-cadherin involved in mouse embryonic brain morphogenesis. Development 1992, 116:1011-1019.
57. Smith M.P., Fletcher-Turner A., Yurek D.M., Cass W.A. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res 2006, 31:533-539.
58. Stio M., Celli A., Treves C. Synergistic anti-proliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J Steroid Biochem Mol Biol 2001, 77:213-222.
59. Suzuki M., Yoshioka M., Hashimoto M., Murakami M., Noya M., Takahashi D., Urashima M. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013, 97:1004-1013.
60. Toell A., Polly P., Carlberg C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem J 2000, 352(Pt 2):301-309.
61. Valipour G., Saneei P., Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab 2014, 99:3863-3872.
62. Veenstra T.D., Prufer K., Koenigsberger C., Brimijoin S.W., Grande J.P., Kumar R. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res 1998, 804:193-205.
63. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001, 904:67-75.
64. Wu W., Zhang X., Zanello L.P. 1alpha,25-dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma. Cancer Lett 2007, 254:75-86.
65. Xie H.R., Hu L.S., Li G.Y. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 2010, 123:1086-1092.
66. Zhang J., Woodhead G.J., Swaminathan S.K., Noles S.R., McQuinn E.R., Pisarek A.J., Stocker A.M., Mutch C.A., Funatsu N., Chenn A. Cortical neural precursors inhibit their own differentiation via N-cadherin maintenance of beta-catenin signaling. Dev Cell 2010, 18:472-479.